The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool
- 16 March 2017
- journal article
- research article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 54 (3) , 323-330
Abstract
Background Alkaptonuria (AKU) is a rare, debilitating autosomal recessive disorder affecting tyrosine metabolism. Deficiency of homogentisate 1,2-dioxygenase leads to increased homogentisic acid (HGA) which is deposited as ochronotic pigment. Clinical sequelae include severe early onset osteoarthritis, increased renal and prostate stone formation and cardiac complications. Treatment has been largely based on analgaesia and arthroplasty. The National AKU Centre in Liverpool has been using 2mg nitisinone (NTBC) off-license for all patients in the United Kingdom with AKU and monitoring the tyrosine metabolite profiles. Methods Patients with confirmed AKU are commenced on 2mg dose (alternative days) of NTBC for three months with daily dose thereafter. Metabolite measurement by LC-MS/MS is performed at baseline, day 4, three-months, six-months and one-year post-commencing nitisinone. Thereafter, monitoring and clinical assessments are performed annually. Results Urine HGA concentration decreased from an average baseline 20,557 μmol/24h (95th percentile confidence interval 18,446-22,669 μmol/24h) by on average 95.4% by six months, 94.8% at one year and 94.1% at two year monitoring. A concurrent reduction in serum HGA concentration of 83.2% compared to baseline was also measured. Serum tyrosine increased from normal adult reference interval to a mean±SD of 594±184 μmol /L at year-two monitoring with an increased urinary excretion from 103±81 μmol /24h at baseline to 1,071±726 μmol /24h two years from therapy. Conclusions The data presented is the first longitudinal survey of NTBC use in an NHS service setting and demonstrates the sustained effect of nitisinone on the tyrosine metabolite profile. Keywords Alkaptonuria, nitisinone, tyrosine, inborn errors of metabolismKeywords
This publication has 29 references indexed in Scilit:
- Ochronosis in a murine model of alkaptonuria is synonymous to that in the human conditionOsteoarthritis and Cartilage, 2012
- Simple and Fast Quantification of Nitisone (NTBC) using Liquid Chromatography-Tandem Mass Spectrometry Method in Plasma of Tyrosinemia Type 1 PatientsJournal of Chromatographic Science, 2012
- A 3-year randomized therapeutic trial of nitisinone in alkaptonuriaMolecular Genetics and Metabolism, 2011
- Current Strategies for the Treatment of Hereditary Tyrosinemia Type IPediatric Drugs, 2006
- Use of nitisinone in patients with alkaptonuriaMetabolism, 2005
- Interaction of (4-Hydroxyphenyl)pyruvate Dioxygenase with the Specific Inhibitor 2-[2-Nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedioneBiochemistry, 2003
- Natural History of AlkaptonuriaNew England Journal of Medicine, 2002
- Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dioneToxicology and Applied Pharmacology, 1995
- Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenaseThe Lancet, 1992
- Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathyThe American Journal of Medicine, 1963